NASDAQ
OKYO
Last Price
US $1.57
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
OKYO Pharma Limited carries no debt; cash flow comfortably covers obligations.
Financial stability - Healthy cash flow growth.
OKYO Pharma Limited's free cash flow has increased -80.91% from $-9.49M last year to $-1.81M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
OKYO Pharma Limited's debt to equity ratio is -0.05, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
OKYO Pharma Limited has insufficient data to evaluate this check.
Financial risk - Net debt/EBITDA.
OKYO Pharma Limited has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
OKYO Pharma Limited carries no debt; interest obligations are fully covered.
Financial risk - Profit margin growth.
OKYO Pharma Limited has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
OKYO Pharma Limited's short-term liabilities of $9.23M exceed its short-term assets of $3.68M, signaling financial risk
Decreasing performance - ROA.
OKYO Pharma Limited's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
OKYO Pharma Limited's return on equity of 102.92%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
OKYO Pharma Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
OKYO Pharma Limited had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
OKYO Pharma Limited has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
OKYO Pharma Limited has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
OKYO Pharma Limited's yearly earnings has increased -72.03% since last year from $-16.83M to $-4.71M, signaling increasing performance
Increasing performance - Healthy revenue growth.
OKYO Pharma Limited's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Increasing performance - ROIC.
ROIC 154.22% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
OKYO Pharma Limited has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
OKYO Pharma Limited had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
OKYO Pharma Limited had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
OKYO Pharma Limited has insufficient data to evaluate this check.
Overvalued - Earnings yield.
OKYO Pharma Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
OKYO Pharma Limited is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
OKYO Pharma Limited has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
OKYO Pharma Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
OKYO Pharma Limited has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
OKYO Pharma Limited has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
102.92%
Return on equity
ROIC: 154.22%
Valuation History
-14.2X
Price to Earnings
EV/EBITDA: -5.8X
Cash flow
Profit margin
-26.56%
(FY vs FY)
Cash flow Y/Y
-7.88%
(FY vs FY)
Fair Value
Market $1.57
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.